http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2002502595-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70503 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-472 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 |
| filingDate | 1999-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2002-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2002502595-A |
| titleOfInvention | Compositions and methods for inhibiting complement C5b-9 complex formation |
| abstract | (57) [Summary]nDisclosed are compounds that modulate CD59-mediated complement activity, compositions comprising these compounds, and methods of making these compounds and methods of using these compounds. These are based on the identification of hu CD59 amino acid residues that act as binding sites for the CD59-C9 interaction. These residues correspond to amino acid residues 42-58 and bind to the region of C9 corresponding to human 334-418, and more particularly, between amino acid residues 359 and 384. Compounds can be derived using this basic amino acid sequence and corresponding to the three-dimensional structure within the protein using any of several techniques known to those of skill in the art, including , Theoretical drug design and modeling of peptide / protein-ligand binding using computer databases, and antibodies and anti-idiotype antibodies raised against proteins or peptides containing this peptide sequence, as well as modified peptides. Those compounds that mimic the structure and / or function of a peptide region are referred to herein as “peptidomimetics” and are small molecules that present a surface that exposes the side chains of these amino acids at the same relative position , Compounds which bind to the active portion of human C9, identified by combinatorial chemistry techniques, as well as modified peptides. This compound can be used to inhibit complement by binding to C9, similarly by binding to CD59, or to maintain complement inhibition by blocking the binding of CD59 to C9. The compound may be administered to a patient in need thereof in an effective amount, in any suitable carrier, locally or systemically, for either inhibiting or blocking inhibition of complement, in a patient in need of such treatment. Can be administered. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013502428-A |
| priorityDate | 1998-02-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 185.